The NHS England Cancer Drugs Fund: A Critical Appraisal and the Case for Radiotherapy Investment

December 25, 2025

The NHS England Cancer Drugs Fund: A Critical Appraisal and the Case for Radiotherapy Investment

10 Key Takeaway Points: NHS Cancer Drugs Fund & the Case for Radiotherapy Investment

The CDF Transformed from Crisis to Success: The original Cancer Drugs Fund (2011-2016) faced a catastrophic funding crisis, overspending by 37% in 2015/16 (reaching £466 million against a £340 million budget). The 2016 reform introduced managed access agreements with clear exit criteria, creating a sustainable model where 86.5% of drugs successfully transition to routine commissioning after evidence accumulation.
Over 100,000 Patients Have Benefitted from Managed Access: Since July 2016, the reformed CDF has enabled 104,267 patients to access 117 different cancer drugs treating 284 cancer indications, with 64,000 patients receiving treatments through negotiated discounts during managed access periods—demonstrating both accessibility and fiscal sustainability.
UK Cancer Survival Rates Lag Dangerously Behind Europe: The UK ranks 28th for lung cancer survival (13-15% vs. 20-25% in best European performers), 26th for colon cancer (58-60% vs. 70-75% elsewhere), and up to 25 years behind some European countries overall. These gaps exist despite similar access to EMA-approved drugs, suggesting systemic infrastructure problems.
Immunotherapy Access Has Been Transformative: Checkpoint inhibitors like pembrolizumab, nivolumab, and atezolizumab, accessed through the CDF, revolutionised treatment for multiple cancer types. CAR-T cell therapies represent "the first full access deal in Europe" for curative cellular therapy, demonstrating the CDF's capacity to negotiate complex arrangements.
Radiotherapy Contributes 40% of Cancer Cures but Receives Only 5% of Cancer Spending: Despite being required by 50% of cancer patients and costing approximately £150-370 per treatment (vastly cheaper than immunotherapy drugs), radiotherapy receives only £440 million annual funding compared to the CDF's dedicated £340 million. This funding disparity is scientifically unjustifiable.
UK Radiotherapy Infrastructure Falls Well Below European Standards: The UK has only 4.8 linear accelerators per million population (13th out of 28 European countries), well below the 5.9 European average and the 8.0 optimal standard. Only 35% of UK cancer patients receive radiotherapy versus the 50% evidence-based benchmark, with 61% of NHS trusts reporting inadequate equipment.
Radiation Oncology Research Funding Is Critically Underfunded: Less than 0.5% of total NIH funding supports radiation oncology research despite it treating ~60% of cancer patients. Similar underinvestment likely exists in the UK, threatening future innovation in rapidly advancing techniques like stereotactic radiotherapy and molecular radiotherapy.
EMA Drug Approvals Don't Automatically Translate to NHS Access: While 52% of EMA-approved medicines are available to English patients, this represents a decline from 66% in 2023. The CDF helps address this gap, but UK new medicine availability still lags other major healthcare systems despite being an innovation leader.
A Dedicated Radiation therapy innovation and access fund could transform outcomes: Modelling suggests that moving from 35% to 50% radiotherapy utilization (closing the gap to evidence-based optimal levels) could save thousands of additional lives annually. A £340 million annual radiotherapy fund—matching CDF allocation—would fund infrastructure, innovation in techniques, and research while remaining extraordinarily cost-effective.
Rebalancing Cancer Investment Requires Both Pharmaceuticals and Radiotherapy: The CDF's success should not obscure that optimal cancer care requires synergistic investment in both systemic therapies and radiation infrastructure. The patient receiving CDF-funded immunotherapy also needs access to modern radiotherapy equipment and expertise; the current imbalance means both investments underperform their potential.

The NHS England Cancer Drugs Fund: A Critical Appraisal and the Case for Radiotherapy Investment

The NHS England Cancer Drugs Fund (CDF) represents one of the most significant and controversial healthcare funding initiatives of the past fifteen years. Established in 2011 as a temporary solution to provide access to cancer drugs rejected by NICE on cost-effectiveness grounds, the CDF has undergone dramatic transformation, faced existential crises, and emerged as a globally unique managed access scheme. However, as we examine its journey from inception through reform to current operations, critical questions emerge about funding priorities in cancer care—particularly when radiotherapy, which contributes to 40% of cancer cures, receives proportionally less investment than novel pharmaceuticals. This analysis explores the CDF's history, its impact on cancer outcomes, and makes the case for a parallel funding model for radiation oncology research and innovation.^[1]^[2]^[3]

The Origins and Early Years: Promise and Problems (2010-2016)

The Cancer Drugs Fund emerged from a perfect storm of political pressure, patient advocacy, and pharmaceutical innovation. Prior to 2010, cancer patients in England faced a stark reality: if NICE deemed a drug too expensive relative to its clinical benefit, it remained inaccessible on the NHS, creating what campaigners termed a "postcode lottery" where private payment determined access. The coalition government's 2010 agreement promised change, and in April 2011, the CDF launched with an initial budget of £50 million, designed as a bridge to a planned value-based pricing system for medicines.^[1]^[2]^[4]

Initially, the CDF appeared successful. By March 2015, over 74,000 patients had accessed treatments through the fund, with the most common drugs—bevacizumab, abiraterone, bendamustine, and cetuximab—accounting for 71% of patients supported. The budget expanded rapidly from £50 million in 2010/11 to £200 million in subsequent years, reflecting growing demand and political commitment.^[2]^[4]^[1]

The Cancer Drugs Fund experienced significant budget overruns between 2013 and 2016, with expenditure exceeding budget by 37% in 2015/16, leading to urgent reforms.

However, beneath this apparent success, fundamental problems festered. The CDF operated without clear exit criteria for drugs, creating an ever-expanding list of treatments funded indefinitely regardless of accumulating evidence. By 2013-14, costs began spiraling beyond budget allocations. The fund overspent by £56 million in 2013-14, with expenditure reaching £256 million against a £280 million budget. The following year proved worse: 2014-15 saw expenditure of £297 million, and by 2015-16, the fund catastrophically overspent, reaching £466 million against a £340 million budget—a 37% overspend.^[2]^[5]^[4]

The overspending forced NHS England to take unprecedented action, removing drugs from the CDF list for the first time in March 2015, and announcing further removals in September 2015. Perhaps most troublingly, due to lack of robust data collection, it proved impossible to evaluate whether the fund had meaningfully improved patient outcomes or survival. The Cancer Taskforce and Public Accounts Committee called for urgent reform.^[5]^[4]^[2]

The 2016 Reform: From Crisis to Managed Access

Faced with fiscal crisis and mounting criticism, NHS England and NICE embarked on radical reform. Following extensive consultation, the reformed CDF launched on 29 July 2016, representing a fundamental reconceptualization from an open-ended funding mechanism to a sophisticated managed access scheme with clear entry and exit criteria.^[5]^[3]^[6]

The reformed CDF introduced three key innovations that transformed cancer drug appraisal in England. First, NICE gained the power to make three types of recommendations rather than the previous binary yes/no decision: "recommended for routine commissioning," "not recommended," or critically, "recommended for use within the CDF". This third option allowed drugs showing clinical promise but with remaining uncertainties about long-term effectiveness to enter a managed access period, typically up to two years, during which additional data would be collected to resolve these uncertainties.^[7]^[3]^[6]^[5]

Second, the new system introduced interim funding agreements (IFAs) that provide immediate funding for drugs receiving positive NICE recommendations, eliminating the previous 90-day delay between guidance publication and NHS availability. This means patients can access newly approved treatments months earlier than under the old system—a benefit that has extended to over 24,595 patients as of 2024.^[8]^[3]

Third, and most importantly, the reformed CDF established managed access agreements (MAAs) negotiated between NHS England and pharmaceutical companies. Under MAAs, drugs enter the CDF at significantly discounted prices while real-world data from NHS usage, combined with ongoing clinical trial results, accumulates to inform a subsequent NICE re-appraisal.^[6]^[9]^[8]

The reformed CDF operates within a fixed annual budget of £340 million, with robust expenditure control mechanisms to prevent the overspending that plagued the original scheme. By the second quarter of 2024/25, the fund remained within its envelope, with £86.80 million spent through quarters 1-2 (£5.35 million on IFAs and £81.45 million on MAAs).^[3]^[8]^[5]

Drugs Introduced Through the CDF

The CDF has funded access to numerous transformative cancer therapies that have changed treatment paradigms. Among the most significant are the immune checkpoint inhibitors, early access to revolutionary CAR-T cell therapies. Axicabtagene ciloleucel (Yescarta) became available through "the first full access deal in Europe for CAR-T therapy," potentially offering cure for some children and adults with blood cancers where other treatments failed. This represented a watershed moment demonstrating the CDF's capacity to negotiate complex arrangements for extremely expensive but potentially curative therapies.^[11]^[6]. Beyond immunotherapies and cellular therapies, the CDF has funded targeted agents across cancer types. For haematological malignancies, drugs like bendamustine became among the most frequently used CDF medications, accounting for a significant proportion of patients supported by the original fund.^[2]^[4]^[11]

Since July 2016, approximately 104,267 patients have received treatment through 117 drugs treating 284 different cancer indications under the reformed system. Of these, over 64,000 patients accessed new treatments through managed access agreements negotiated at significantly discounted prices to the NHS. This represents a substantial increase in both the number of patients benefiting and the efficiency of spending compared to the original CDF's 95,000 patients served between 2011-2015.^[8]^[2]

Of 37 drugs re-appraised after managed access in the reformed Cancer Drugs Fund, 86.5% received approval for routine NHS commissioning, demonstrating the effectiveness of the data collection process.

CDF Performance: Re-appraisal Success Rates and Evidence Generation

The true test of the reformed CDF lies in what happens when drugs exit their managed access period and face re-appraisal by NICE based on accumulated evidence. Here, the results are remarkably positive. As of the fourth quarter of 2023-24, 60 managed access agreements have been agreed between companies and the CDF since July 2016. Of these, 37 treatments completed re-appraisal, and 32 (86.5%) received recommendations for routine commissioning in the patient population referred to the CDF.^[9]^[14]

Only two treatments (5.4%) were not approved for routine use on review, while three (8.1%) were terminated either because companies failed to provide complete evidence submissions for re-appraisal or because the product license was withdrawn.^[14]^[9]

Industry analysis of CDF outcomes reveals additional insights into the scheme's performance. Life-year gains were observed to be 12% greater on exit from the CDF compared to initial predictions at entry, suggesting that initial clinical benefit estimates were, if anything, conservative. The average time spent in the CDF was 2.7 years—just over half the maximum five-year period—with timing primarily driven by data availability from pivotal trials rather than real-world data collection.^[14]

Interestingly, despite the managed access period, NICE committees acknowledged at re-appraisal that substantial uncertainties often remained, with 63% of resubmissions still citing limited data collected within the CDF. An analysis of 39 CDF cases identified 108 key uncertainties, averaging three per appraisal, with overall survival being the most commonly identified uncertainty followed by generalisability of evidence to the target population. Fewer than half (43.6%) of data collection arrangements addressed all key uncertainties identified by NICE committees.^[15]^[14]

This raises important questions about whether uncertainty is genuinely being resolved during the CDF period or whether NICE has pragmatically accepted higher levels of uncertainty for promising cancer treatments. The fact that committees make positive recommendations despite acknowledging remaining uncertainty suggests that the managed access period serves multiple purposes beyond pure evidence generation—providing patient access, demonstrating NHS commitment to innovation, and creating leverage for price negotiations with pharmaceutical companies.^[14]

CDF and EMA Approvals: Regulatory Alignment and Divergence

The relationship between the CDF and European Medicines Agency (EMA) regulatory approvals reveals important insights into how the UK balances access with evidence standards. Unlike the EMA, which assesses safety and efficacy to grant marketing authorisation across the European Union, NICE evaluates cost-effectiveness to make funding recommendations specifically for the NHS. This creates potential for divergence: a drug may have EMA approval (deemed safe and effective) but lack NICE recommendation (deemed insufficiently cost-effective).^[16]

International comparisons demonstrate that the UK has historically lagged other major regulatory authorities in both approval rates and timelines. Analysis of 154 medicines across multiple therapeutic areas between 2016-2023 found that the FDA approved 84 medicines (55%) and EMA approved 80 (52%), while the MHRA approved only 71 (46%). More strikingly, the FDA and EMA approved medicines on average 360 days and 86 days faster than the MHRA, respectively.^[17]^[18]

For cancer drugs specifically, research comparing approvals between 2009-2013 found that of 45 anticancer drug indications approved in the United States, 67% (30) were approved by the EMA and therefore potentially available in the UK. The remaining 33% either were never submitted to the EMA or were rejected, creating access gaps that the CDF was designed to address.^[16]

The reformed CDF has helped narrow this gap by creating pathways for drugs approved by EMA but initially rejected by NICE on cost-effectiveness grounds. However, the UK still faces challenges in new medicine availability. According to EFPIA data, 56% of new medicines approved by the EMA were available to English patients in 2024, down from 66% in 2023. This decline is concerning and suggests that despite the CDF, broader systemic issues affect access to innovative treatments in the UK.^[19]

Uptake of new cancer medicines varies dramatically across Europe, with Austria, Switzerland, and France leading while Latvia, Poland, Estonia, and Slovakia have the lowest uptake. The UK falls somewhere in the middle of this spectrum, performing better than Central and Eastern European countries but behind some Western European peers.^[20]^[21]

UK Cancer Outcomes: A Sobering International Comparison

Despite the CDF's investment in novel therapies, UK cancer survival rates remain disappointingly behind comparable European countries—a reality that should prompt serious reflection about whether pharmaceutical innovation alone can close these gaps. Analysis by the Less Survivable Cancers Taskforce in January 2024 ranked the UK among 33 comparable countries for 5-year survival rates: 16th for liver cancer, 21st for oesophageal cancer, 25th for brain cancer, 26th for pancreatic cancer, and a dismal 28th for lung and stomach cancers. Only 16% of UK patients diagnosed with these six cancer types are projected to survive beyond five years.^[22]

The OECD's 2024 analysis found the UK positioned at 31st place out of 43 countries for five-year survival in lung cancer—the leading cause of cancer deaths with approximately 34,800 UK fatalities annually. For colon cancer, the second most prevalent cause of cancer mortality claiming 16,800 lives yearly, the UK ranks 26th, trailing South Korea, Belgium, and New Zealand. While the UK performs better for breast cancer, surpassing OECD and EU averages, it still ranks only 23rd among 45 countries evaluated.^[23]

Macmillan analysis suggests that UK cancer survival rates lag up to 25 years behind other European countries. If the UK achieved Germany's cancer survival rates, just over 35,000 more people would be alive five years after diagnosis; if the UK matched France's cancer death rates, more than 100,000 women's deaths could be prevented over the next decade. Research on colon cancer shows that Denmark increased five-year survival rates from less than 60% for those diagnosed in 2007-2011 to more than 70% in recent figures, while England showed little to no improvement over the same period.^[24]^[25]^[26]

Importantly, these survival disparities exist despite the UK performing reasonably well on cancer screening uptake, holding the seventh highest cervical cancer screening rate out of 30 countries and eleventh highest for breast cancer screening. This suggests that screening alone cannot compensate for deficiencies in treatment infrastructure, timeliness, and access.^[23]

The UK does show some positive trends. Cancer mortality decreased substantially over 25 years (1993-2018) in adults aged 35-69, with age-standardised mortality rates reducing by 37% in men and 33% in women. Cancer deaths dropped 22% since the 1970s according to Cancer Research UK's 2025 report. These improvements likely reflect successes in prevention (smoking reduction), earlier detection (screening programmes), and improved treatments.^[27]^[28]^[29]

However, the UK continues to underperform relative to its economic position and research capacity. Performance against cancer waiting times targets fell to among the worst on record in 2023 and 2024. Early diagnosis rates in England, while showing the first increase in a decade, reached only 56.1% by December 2023—still far short of the 75% target for 2028. This suggests systemic problems beyond access to novel drugs.^[25]^[27]

Radiotherapy in the UK: The Neglected Pillar of Cancer Care

While the CDF receives £340 million annually for novel pharmaceuticals, radiotherapy—which contributes to 40% of all cancer cures—operates on a total annual budget of approximately £440 million for all services, representing just 5% of national cancer spending. This funding disparity becomes even more striking when one considers that radiotherapy is required in 50% of cancer treatments and is described as the most cost-effective cancer treatment modality.^[30]^[31]^[32]^[33]

The cost-effectiveness of radiotherapy is remarkable. Estimates suggest radiotherapy costs approximately £370 per fraction (single treatment visit), which can reduce to around £150 per treatment over a 25-fraction course since most costs are incurred during planning and preparation. Australian research calculated the cost per five-year overall survival at AU$86,480 (approximately £44,000), translating to just AU$17,296 (£8,800) per one-year overall survival—extraordinarily cost-effective by any healthcare standard.^[34]^[33]

Yet despite this cost-effectiveness and clinical impact, UK radiotherapy infrastructure lags significantly behind European standards. The UK has only 4.8 linear accelerators (LINACs) per million population, ranking 13th out of 28 European countries, well below the European average of 5.9 and the optimal standard of approximately 8.0. In terms of patient access, only 35% of UK cancer patients receive radiotherapy, falling below the 40% European average and substantially short of the 50% global benchmark that evidence suggests is optimal.^[31]^[35]^[36]

This underutilisation has serious consequences. Radiotherapy UK's 2021 survey found that 61% of participating NHS trusts lack sufficient equipment to handle current demand—a figure certain to worsen as cancer incidence rises while service capacity stagnates. Many UK LINACs are more than a decade old, and equipment shortages mean that four-week delays in starting treatment—which reduce survival rates by 10%—are not uncommon.^[36]^[31]

International comparisons reveal the scale of the problem. Less than 17% of European countries treat at least 80% of optimal radiotherapy indications, and 46% of European countries treat fewer than 70% of patients with radiotherapy indications. The UK falls into this underperforming category. In Norway, following implementation of the Norwegian Cancer Plan that increased radiotherapy capacity, utilisation increased to 42.5% by 2010—still below the evidence-based optimum of 53% but substantially better than the UK's 35%.^[35]

Research demonstrates that more than one in four European cancer patients who need radiotherapy do not receive it, with limited availability of trained personnel and equipment being major causes of this underutilisation. The UK faces severe workforce crises across therapeutic radiographers, clinical oncologists, and radiation physicists, with a 30% radiologist workforce shortfall (equivalent to 1,962 doctors) as of 2024. In 2023, the NHS spent £276 million managing excess reporting demand due to this shortage.^[37]^[35]

Recent government investment provides some hope. In 2024, £70 million was allocated to purchase 28 new cutting-edge LINAC machines for NHS trusts across England, funded through the Plan for Change. These machines use modern technology to reduce treatment delays and could halve the number of hospital visits needed for some patients, potentially delivering up to 27,500 additional treatments per year by March 2027.^[38]^[39]^[40]

While welcome, this £70 million investment pales in comparison to the accumulated underfunding. The Radiotherapy Innovation Fund, established to support advanced radiotherapy delivery, received just £23 million—described as "relatively modest, especially in comparison with funding provided to other areas". NHS England spends approximately £440 million annually on radiotherapy services, with an additional £56 million invested in the new Proton Beam Therapy service and a £130 million capital programme for equipment replacement. Even combining these investments, total radiotherapy funding over multiple years barely exceeds a single year's Cancer Drugs Fund allocation.^[41]^[30]

The funding model itself creates barriers. Individual NHS trusts are responsible for maintaining and replacing high-value equipment, forcing trusts to prioritise investments amidst competing demands. Radiotherapy often loses out to more visible priorities like A&E services, despite its proven effectiveness.^[31]^[41]

The Research Funding Gap: Radiotherapy's Cinderella Status

Beyond service delivery, radiotherapy suffers from chronic underinvestment in research—a disparity that threatens future innovation and improvement in this critical treatment modality. In the United States, where comprehensive data is available, less than 0.5% of the total NIH budget supports radiation oncology research, and fewer than 2% of National Cancer Institute funds are allocated to radiation oncology—proportions that have remained unchanged over the past decade despite radiation therapy's essential role in cancer care.^[42]^[43]

Similar patterns likely exist in the UK, though comprehensive data is less readily available. The National Cancer Research Institute, a partnership of government and charity members with collective spend of £650 million on cancer research in 2018/19, includes radiation oncology within its portfolio, but specific allocation data suggests disproportionately low investment relative to clinical impact. Cancer Research UK's new strategy to invest in radio-biology and radiotherapy is welcome but comes after decades of relative neglect.^[30]

The underlying causes are multifaceted: lack of awareness among funding bodies about radiation therapy's integral role, possible disproportionate representation in leadership positions within funding agencies creating allocation bias, and insufficient advocacy from the radiation oncology community.^[42]^[43]

A Radiation Oncology Fund: The Case for Parity

The evidence compellingly supports creation of a dedicated funding mechanism for radiation oncology equivalent to the Cancer Drugs Fund

The case for this rests on multiple pillars. First, cost-effectiveness: radiotherapy delivers exceptional value, costing approximately £150-370 per fraction compared to immunotherapy drugs that cost tens of thousands of pounds per patient. If even a fraction of CDF-level investment flowed into radiotherapy infrastructure and research, the return in life-years saved would likely exceed pharmaceutical investments given radiotherapy's proven efficacy and broader applicability across cancer types.^[34]^[33]

Second, accessibility and equity: unlike drugs that benefit specific molecular subsets (e.g., PD-L1 positive patients for checkpoint inhibitors), radiotherapy can treat virtually all solid tumours and many haematological malignancies. Expanding radiotherapy access addresses survival disparities more equitably than drugs targeting molecular subgroups.^[31]^[35]^[36]^[32]

Third, innovation potential: radiation oncology stands at the cusp of revolutionary advances—stereotactic ablative body radiotherapy (SABR), molecular radiotherapy (MRT), proton beam therapy, and carbon ion radiotherapy. These techniques offer hypofractionation (fewer treatments with higher doses), improved normal tissue sparing, and potential cost savings through reduced hospital visits. Yet commissioning and funding structures inhibit innovation and create unequal access to these novel approaches. A dedicated fund could accelerate adoption and generate the evidence needed for routine commissioning, exactly as the reformed CDF does for drugs.^[30]^[45]^[46]

Fourth, workforce development: the 30% radiologist shortage and severe deficits in therapeutic radiographers and clinical oncologists cannot be addressed without sustained funding for training, retention, and research career development. Research funding creates academic infrastructure that attracts and develops the next generation of radiation oncologists. ld.^[43]^[37]

The Survival Impact: What the Evidence Suggests

Norway's experience is instructive: implementation of the Norwegian Cancer Plan increased radiotherapy capacity, utilisation rose to 42.5%, and cancer outcomes improved measurably. Denmark's colon cancer survival increased from under 60% to over 70% during a period when England's remained stagnant—a disparity unlikely to be explained by drugs alone given similar EMA drug approvals across EU countries.^[26]^[35]

Mathematical modelling suggests the potential impact. Radiotherapy contributes 23% population-level five-year local control and 6% five-year overall survival benefit across all cancers. If the UK moved from 35% to 50% radiotherapy utilisation (a 43% relative increase), and assuming linear relationships (a conservative assumption since those currently not receiving indicated radiotherapy likely have worse prognoses), the additional patients receiving optimal treatment could translate to thousands of additional five-year survivors annually.^[34]

For specific cancer types, the impact would be profound. In lung cancer, where the UK ranks 28th in Europe and has 34,800 annual deaths, even a modest 2-3 percentage point improvement in five-year survival (from approximately 15% to 17-18%) would save over 1,000 lives annually. For colon cancer with 16,800 annual deaths, closing the gap toward Denmark's 70% five-year survival could prevent thousands of premature deaths.^[22]^[23]^[26]

Radiotherapy's role in early-stage disease is particularly important for achieving the Long Term Plan's goal of 75% early diagnosis. Early-stage cancers are often curable with radiotherapy alone or in combination with surgery, avoiding the need for systemic therapy with its attendant toxicities and costs. Expanded access to SABR for early lung cancer, for example, provides outcomes comparable to surgery but with shorter recovery and applicability to patients unfit for operation.^[30]^[27]

The complementary nature of radiotherapy and systemic therapy means that investment in both, rather than the current pharmaceutical-heavy allocation, would likely produce synergistic survival gains. Many cancer treatments combine radiotherapy with chemotherapy or immunotherapy; inadequate radiotherapy infrastructure limits the effectiveness of even the best drugs.

1. Establish the Radiation Therapy Innovation and Access Fund (RTIAF) with £340 million annual allocation, structured in three streams as outlined above, with governance mirroring the successful CDF partnership between NHS England, NICE, and clinical specialties but led by radiation oncology expertise.^[30]^[31]^[41]

, removing the perverse incentive to offer suboptimal treatment to stay within budgets.^[41]^[45]

Conclusion: Rebalancing Priorities for Optimal Cancer Care

The NHS England Cancer Drugs Fund represents a remarkable policy innovation. Its transformation from an unsustainable, evidence-poor funding mechanism into a sophisticated managed access scheme demonstrates health system adaptability and commitment to pharmaceutical innovation. The 86.5% success rate of drugs exiting managed access and the 104,267 patients who have benefitted since 2016 stand as testament to the reformed CDF's value.^[8]^[9]^[14]

However, this success must not obscure fundamental imbalances in cancer care investment. While novel pharmaceuticals receive £340 million annually through a dedicated, high-profile fund, radiotherapy—contributing to 40% of cancer cures and required by 50% of cancer patients—operates on a total budget of £440 million for all services and receives a tiny fraction of cancer research funding. This disparity is scientifically unjustifiable..^[42]^[43]^[30]^[31]^[33]

The UK's disappointing cancer survival rankings—28th for lung cancer, 26th for colon cancer, up to 25 years behind European leaders—cannot be explained by pharmaceutical access alone given similar EMA drug approvals across Europe. The gap more likely reflects systemic factors including late diagnosis, treatment delays, and inadequate radiotherapy capacity. If the UK achieved Sweden's cancer survival rates across all types, almost 200,000 deaths could be avoided annually—far more than any single drug or even all CDF drugs combined could achieve.^[16]^[22]^[23]^[20]^[26]^[31]^[35]

Having a separate fund for Radiotherapy access, innovation and research would not compete with pharmaceutical innovation but complement it, recognising that optimal cancer care requires both cutting-edge systemic therapies and world-class radiation services. The patient with metastatic melanoma receiving pembrolizumab through the CDF also needs access to SABR for oligometastatic disease. Investment in one without the other produces suboptimal outcomes and poor value.

As we look toward the next decade of cancer care in England, the challenge is not choosing between drugs and radiotherapy but ensuring both receive investment proportional to their clinical contribution. The Cancer Drugs Fund has demonstrated that dedicated funding with clear governance, managed access, robust data collection, and stakeholder partnership can transform access and generate evidence. Applying these principles to radiotherapy through a parallel fund would position the UK to achieve the Long Term Plan's ambitions, move toward European survival leadership, and fulfil the promise that all cancer patients receive world-class care regardless of whether their treatment comes in a vial or from a linear accelerator.^[27]

Despite radiotherapy contributing to 40% of cancer cures, it receives only £440 million annually (5% of cancer spending), while the Cancer Drugs Fund allocates £340 million specifically for novel oncology drugs.

"Transparency note: This article was researched and drafted with the assistance of AI tools (Perplexity AI) to gather evidence, analyze data, and structure arguments. All clinical perspectives, analysis, and recommendations represent my professional expertise as a radiation oncologist. I am fully responsible for the accuracy and content of this work."

1. https://en.wikipedia.org/wiki/Cancer_Drugs_Fund

2. https://www.nao.org.uk/reports/investigation-into-the-cancer-drugs-fund/

3. https://www.england.nhs.uk/cancer/cdf/

4. https://www.kingsfund.org.uk/insight-and-analysis/blogs/cancer-drugs-fund-inequitable-inefficient

5. https://www.england.nhs.uk/wp-content/uploads/2013/04/cdf-sop.pdf

6. https://www.pharmaceutical-technology.com/features/cancer-drugs-fund-nhs-reimbursement/

7. https://www.bowelcanceruk.org.uk/news-and-blogs/research-blog/reforming-the-cancer-drugs-fund/

8. https://www.england.nhs.uk/long-read/cancer-drugs-fund-activity-update-q2-2024-25/

9. https://www.england.nhs.uk/long-read/cancer-drugs-fund-activity-update-q4-2023-24/

10. https://www.nice.org.uk/guidance/ta713/documents/final-appraisal-determination-document-2

11. https://www.england.nhs.uk/wp-content/uploads/2017/04/National-Cancer-Drugs-Fund-list-version-1.298.pdf

12. https://www.nice.org.uk/guidance/ta520/documents/appraisal-consultation-document-2